BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 34523186)

  • 21. Frequency of MYD88 and CD79B mutations, and MGMT methylation in primary central nervous system diffuse large B-cell lymphoma.
    Zheng M; Perry AM; Bierman P; Loberiza F; Nasr MR; Szwajcer D; Del Bigio MR; Smith LM; Zhang W; Greiner TC
    Neuropathology; 2017 Dec; 37(6):509-516. PubMed ID: 28856744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma.
    Camus V; Sarafan-Vasseur N; Bohers E; Dubois S; Mareschal S; Bertrand P; Viailly PJ; Ruminy P; Maingonnat C; Lemasle E; Stamatoullas A; Picquenot JM; Cornic M; Beaussire L; Bastard C; Frebourg T; Tilly H; Jardin F
    Leuk Lymphoma; 2016 Sep; 57(9):2171-9. PubMed ID: 26883583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Experience of Cerebrospinal Fluid-Based Liquid Biopsy Demonstrates Superiority of Cell-Free DNA over Cell Pellet Genomic DNA for Molecular Profiling.
    Bale TA; Yang SR; Solomon JP; Nafa K; Middha S; Casanova J; Sadowska J; Skakodub A; Ahmad H; Yu HA; Riely GJ; Kris MG; Chandarlapaty S; Rosenblum MK; Gavrilovic I; Karajannis MA; Pentsova E; Miller A; Boire A; Mellinghoff I; Berger MF; Zehir A; Ladanyi M; Benayed R; Arcila ME
    J Mol Diagn; 2021 Jun; 23(6):742-752. PubMed ID: 33781965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Highly sensitive
    Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
    Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. MYD88 L265P MUTATION DETECTION IN THE AQUEOUS HUMOR OF PATIENTS WITH VITREORETINAL LYMPHOMA.
    Miserocchi E; Ferreri AJM; Giuffrè C; Cangi MG; Francaviglia I; Calimeri T; Ponzoni M; Pecciarini L; Bandello FM; Modorati GM
    Retina; 2019 Apr; 39(4):679-684. PubMed ID: 30204732
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
    Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
    Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.
    Shi H; Zhou X; Chen B; Xiao J; Li Y; Zhou X; Zhou Q; Chen K; Wang Q
    Ocul Immunol Inflamm; 2021 Apr; 29(3):448-455. PubMed ID: 31603365
    [No Abstract]   [Full Text] [Related]  

  • 28. Digital PCR-Based Detection of EGFR Mutations in Paired Plasma and CSF Samples of Lung Adenocarcinoma Patients with Central Nervous System Metastases.
    Huang R; Xu X; Li D; Chen K; Zhan Q; Ge M; Zhou X; Liang X; Guan M
    Target Oncol; 2019 Jun; 14(3):343-350. PubMed ID: 31161597
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of MYD88 L265P Mutation Status in the Subclassification of Low-Grade B-Cell Lymphoma/Leukemia.
    Insuasti-Beltran G; Gale JM; Wilson CS; Foucar K; Czuchlewski DR
    Arch Pathol Lab Med; 2015 Aug; 139(8):1035-41. PubMed ID: 26230596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MYD88 (L265P) mutation is associated with an unfavourable outcome of primary central nervous system lymphoma.
    Hattori K; Sakata-Yanagimoto M; Okoshi Y; Goshima Y; Yanagimoto S; Nakamoto-Matsubara R; Sato T; Noguchi M; Takano S; Ishikawa E; Yamamoto T; Matsumura A; Chiba S
    Br J Haematol; 2017 May; 177(3):492-494. PubMed ID: 27161435
    [No Abstract]   [Full Text] [Related]  

  • 31. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.
    Drandi D; Ferrante M; Borriero M; Ferrero S
    Methods Mol Biol; 2023; 2621():57-72. PubMed ID: 37041440
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of tumor-derived cell free DNA(cfDNA) by digital PCR (DigPCR) in cerebrospinal fluid of patients with BRAFV600 mutated malignancies.
    Momtaz P; Pentsova E; Abdel-Wahab O; Diamond E; Hyman D; Merghoub T; You D; Gasmi B; Viale A; Chapman PB
    Oncotarget; 2016 Dec; 7(51):85430-85436. PubMed ID: 27863426
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutations found in cell-free DNAs of patients with malignant lymphoma at remission can derive from clonal hematopoiesis.
    Suehara Y; Sakata-Yanagimoto M; Hattori K; Kusakabe M; Nanmoku T; Sato T; Noguchi M; Chiba S
    Cancer Sci; 2019 Oct; 110(10):3375-3381. PubMed ID: 31436356
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular analysis in liquid biopsies for diagnostics of primary central nervous system lymphoma: Review of literature and future opportunities.
    Hiemcke-Jiwa LS; Leguit RJ; Snijders TJ; Jiwa NM; Kuiper JJW; de Weger RA; Minnema MC; Huibers MMH
    Crit Rev Oncol Hematol; 2018 Jul; 127():56-65. PubMed ID: 29891112
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MYD88 expression and L265P mutation in diffuse large B-cell lymphoma.
    Choi JW; Kim Y; Lee JH; Kim YS
    Hum Pathol; 2013 Jul; 44(7):1375-81. PubMed ID: 23380077
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
    Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
    Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A pilot study on the use of cerebrospinal fluid cell-free DNA in intramedullary spinal ependymoma.
    Connolly ID; Li Y; Pan W; Johnson E; You L; Vogel H; Ratliff J; Hayden Gephart M
    J Neurooncol; 2017 Oct; 135(1):29-36. PubMed ID: 28900844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activating L265P mutations of the MYD88 gene are common in primary central nervous system lymphoma.
    Montesinos-Rongen M; Godlewska E; Brunn A; Wiestler OD; Siebert R; Deckert M
    Acta Neuropathol; 2011 Dec; 122(6):791-2. PubMed ID: 22020631
    [No Abstract]   [Full Text] [Related]  

  • 39. Primary diffuse large B-cell lymphomas of central nervous system exhibit remarkably high prevalence of oncogenic MYD88 and CD79B mutations.
    Yamada S; Ishida Y; Matsuno A; Yamazaki K
    Leuk Lymphoma; 2015 Jul; 56(7):2141-5. PubMed ID: 25347427
    [TBL] [Abstract][Full Text] [Related]  

  • 40. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
    Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
    World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.